Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Advanced Heart Failure and Transplant
Is it reasonable to start de-escalating GDMT for patients with recovered LVEF following PCI for anterior STEMI, and if so, what class of medication would you consider stopping first?
Related Questions
Do you ever consider sodium supplementation to augment diuresis in patients hospitalized with decompensated heart failure, as discussed in a recent systematic review and meta-analysis?
How do you use IVC caliber and collapsibility to guide decisions about diuresis?
How do you consider and approach transition to hospice in a patient with HFrEF who does not appear to tolerate GDMT?
For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?
What are your first-line vasopressors of choice for the management of acute severe aortic regurgitation and persistent hypotension/shock?
Would you consider adding metoprolol succinate to a medication regimen for a patient with paroxysmal Afib on sotalol, known CAD, HF with mildly reduced LVEF, assuming hemodynamics could tolerate it?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
For patients acutely decompensated with ACC Stage C-D, NYHA 3-4, probable INTERMACS 4, how do you decide between MCS devices like CCM Barostim or potentially LVAD?
Do you recommend initiating treatment with an SGLT2 inhibitor or semaglutide first for a patient with obesity and heart failure with preserved ejection fraction?
What are the best techniques to reduce POCUS artifact and increase the diagnostic accuracy of lung ultrasound?
